Hite Christopher reported grant involving 7,122 shares of Royalty Pharma plc at $0.00 for $0 on Nov 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
EVP & Chairman, Partnering
EVP & Chairman, Partnering
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
7,122Class A Ordinary Shares
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
277,523Indirect · By SCH Investment Partners LLC
Trade date
Nov 4, 2026Grant
Filed
Nov 6, 2026, 4:13 PM ET2-day reporting delay
Accession
0001814238-26-000019Code A · Transaction 394754
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

RPRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RPRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −16%1w ago −3.7%1d ago −1.3%
Returns since7d +3%30d90d180d1y

Footnotes in full

F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.